on Galimedix, Inc.
Galimedix Therapeutics Presents Phase 2 Data at EURETINA Congress
Galimedix Therapeutics, a biotechnology company in Phase 2 clinical stages, will present data from its eDREAM study at the 26th EURETINA Congress in Vienna, Austria. The study focuses on geographic atrophy, a severe form of dry age-related macular degeneration, using the neuroprotective therapy GAL-101. The event runs from October 1-4, 2026.
The data highlights patient-tailored microperimetry as a functional endpoint to evaluate treatment effects. Key presentations include topics like the repeatability of personalized microperimetry endpoints and the structure-function discordance in geographic atrophy.
The EURETINA Congress is renowned in the retinal medicine community, enabling experts to exchange the latest scientific and clinical developments in retinal disease treatment and management.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Galimedix, Inc. news